Cargando…
Deficiency in Dipeptidyl Peptidase-4 Promotes Chemoresistance Through the CXCL12/CXCR4/mTOR/TGFβ Signaling Pathway in Breast Cancer Cells
Dipeptidyl peptidase (DPP)-4, a molecular target of DPP-4 inhibitors, which are type 2 diabetes drugs, is expressed in a variety of cell types, tissues and organs. DPP-4 has been shown to be involved in cancer biology, and we have recently shown that a DPP-4 inhibitor promoted the epithelial mesench...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7037814/ https://www.ncbi.nlm.nih.gov/pubmed/31991851 http://dx.doi.org/10.3390/ijms21030805 |
_version_ | 1783500509842243584 |
---|---|
author | Li, Shaolan Fan, Yang Kumagai, Asako Kawakita, Emi Kitada, Munehiro Kanasaki, Keizo Koya, Daisuke |
author_facet | Li, Shaolan Fan, Yang Kumagai, Asako Kawakita, Emi Kitada, Munehiro Kanasaki, Keizo Koya, Daisuke |
author_sort | Li, Shaolan |
collection | PubMed |
description | Dipeptidyl peptidase (DPP)-4, a molecular target of DPP-4 inhibitors, which are type 2 diabetes drugs, is expressed in a variety of cell types, tissues and organs. DPP-4 has been shown to be involved in cancer biology, and we have recently shown that a DPP-4 inhibitor promoted the epithelial mesenchymal transition (EMT) in breast cancer cells. The EMT is known to associate with chemotherapy resistance via the induction of ATP-binding cassette (ABC) transporters in cancer cells. Here, we demonstrated that deficiency in DPP-4 promoted chemotherapy resistance via the CXCL12/CXCR4/mTOR axis, activating the TGFβ signaling pathway via the expression of ABC transporters. DPP-4 inhibition enhanced ABC transporters in vivo and in vitro. Doxorubicin (DOX) further induced ABC transporters in DPP-4-deficient 4T1 cells, and the induction of ABC transporters was suppressed by either the CXCR4 inhibitor AMD3100, the mTOR inhibitor rapamycin or a neutralizing TGFβ (1, 2 and 3) antibody(N-TGFβ). Knockdown of snail, an EMT-inducible transcription factor, suppressed ABC transporter levels in DOX-treated DPP-4-deficient 4T1 cells. In an allograft mouse model, however, the effects of DOX in either primary tumor or metastasis were not statistically different between control and DPP-4-kd 4T1. Taken together, our findings suggest that DPP-4 inhibitors potentiate chemotherapy resistance via the induction of ABC transporters by the CXCL12/CXCR4/mTOR/TGFβ signaling pathway in breast cancer cells. |
format | Online Article Text |
id | pubmed-7037814 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-70378142020-03-10 Deficiency in Dipeptidyl Peptidase-4 Promotes Chemoresistance Through the CXCL12/CXCR4/mTOR/TGFβ Signaling Pathway in Breast Cancer Cells Li, Shaolan Fan, Yang Kumagai, Asako Kawakita, Emi Kitada, Munehiro Kanasaki, Keizo Koya, Daisuke Int J Mol Sci Article Dipeptidyl peptidase (DPP)-4, a molecular target of DPP-4 inhibitors, which are type 2 diabetes drugs, is expressed in a variety of cell types, tissues and organs. DPP-4 has been shown to be involved in cancer biology, and we have recently shown that a DPP-4 inhibitor promoted the epithelial mesenchymal transition (EMT) in breast cancer cells. The EMT is known to associate with chemotherapy resistance via the induction of ATP-binding cassette (ABC) transporters in cancer cells. Here, we demonstrated that deficiency in DPP-4 promoted chemotherapy resistance via the CXCL12/CXCR4/mTOR axis, activating the TGFβ signaling pathway via the expression of ABC transporters. DPP-4 inhibition enhanced ABC transporters in vivo and in vitro. Doxorubicin (DOX) further induced ABC transporters in DPP-4-deficient 4T1 cells, and the induction of ABC transporters was suppressed by either the CXCR4 inhibitor AMD3100, the mTOR inhibitor rapamycin or a neutralizing TGFβ (1, 2 and 3) antibody(N-TGFβ). Knockdown of snail, an EMT-inducible transcription factor, suppressed ABC transporter levels in DOX-treated DPP-4-deficient 4T1 cells. In an allograft mouse model, however, the effects of DOX in either primary tumor or metastasis were not statistically different between control and DPP-4-kd 4T1. Taken together, our findings suggest that DPP-4 inhibitors potentiate chemotherapy resistance via the induction of ABC transporters by the CXCL12/CXCR4/mTOR/TGFβ signaling pathway in breast cancer cells. MDPI 2020-01-26 /pmc/articles/PMC7037814/ /pubmed/31991851 http://dx.doi.org/10.3390/ijms21030805 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Li, Shaolan Fan, Yang Kumagai, Asako Kawakita, Emi Kitada, Munehiro Kanasaki, Keizo Koya, Daisuke Deficiency in Dipeptidyl Peptidase-4 Promotes Chemoresistance Through the CXCL12/CXCR4/mTOR/TGFβ Signaling Pathway in Breast Cancer Cells |
title | Deficiency in Dipeptidyl Peptidase-4 Promotes Chemoresistance Through the CXCL12/CXCR4/mTOR/TGFβ Signaling Pathway in Breast Cancer Cells |
title_full | Deficiency in Dipeptidyl Peptidase-4 Promotes Chemoresistance Through the CXCL12/CXCR4/mTOR/TGFβ Signaling Pathway in Breast Cancer Cells |
title_fullStr | Deficiency in Dipeptidyl Peptidase-4 Promotes Chemoresistance Through the CXCL12/CXCR4/mTOR/TGFβ Signaling Pathway in Breast Cancer Cells |
title_full_unstemmed | Deficiency in Dipeptidyl Peptidase-4 Promotes Chemoresistance Through the CXCL12/CXCR4/mTOR/TGFβ Signaling Pathway in Breast Cancer Cells |
title_short | Deficiency in Dipeptidyl Peptidase-4 Promotes Chemoresistance Through the CXCL12/CXCR4/mTOR/TGFβ Signaling Pathway in Breast Cancer Cells |
title_sort | deficiency in dipeptidyl peptidase-4 promotes chemoresistance through the cxcl12/cxcr4/mtor/tgfβ signaling pathway in breast cancer cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7037814/ https://www.ncbi.nlm.nih.gov/pubmed/31991851 http://dx.doi.org/10.3390/ijms21030805 |
work_keys_str_mv | AT lishaolan deficiencyindipeptidylpeptidase4promoteschemoresistancethroughthecxcl12cxcr4mtortgfbsignalingpathwayinbreastcancercells AT fanyang deficiencyindipeptidylpeptidase4promoteschemoresistancethroughthecxcl12cxcr4mtortgfbsignalingpathwayinbreastcancercells AT kumagaiasako deficiencyindipeptidylpeptidase4promoteschemoresistancethroughthecxcl12cxcr4mtortgfbsignalingpathwayinbreastcancercells AT kawakitaemi deficiencyindipeptidylpeptidase4promoteschemoresistancethroughthecxcl12cxcr4mtortgfbsignalingpathwayinbreastcancercells AT kitadamunehiro deficiencyindipeptidylpeptidase4promoteschemoresistancethroughthecxcl12cxcr4mtortgfbsignalingpathwayinbreastcancercells AT kanasakikeizo deficiencyindipeptidylpeptidase4promoteschemoresistancethroughthecxcl12cxcr4mtortgfbsignalingpathwayinbreastcancercells AT koyadaisuke deficiencyindipeptidylpeptidase4promoteschemoresistancethroughthecxcl12cxcr4mtortgfbsignalingpathwayinbreastcancercells |